1 research outputs found
[Associated factors for prediabetes in patients with human immunodeficiency virus]
No full text<p><strong>Abstract</strong></p><p><strong>Introduction</strong>: HIV disease was transformed from a fatal condition to one with metabolic complications. In Mexico City, the associated factors for prediabetes in this population are unknown; investigating it is relevant to improve their quality of life.</p><p><strong>Objective:</strong> To determine the risk association factors for prediabetes in people living with HIV.</p><p><strong>Material and methods:</strong> Cross-analytical, retrospective study. Records of patients living with HIV were reviewed, exposure factors and fasting glucose concentration were recorded. Patients from 18 to 65 years of age were included, on co-formulated antiretroviral treatment, without adjustment of antiretroviral treatment in the last two years, with a BMI of 18.5-40 kg/m2.</p><p><strong>Results</strong>: 148 patients were included, 68 presented prediabetes. The factors with risk association that were identified are: age over 60 years (OR 9.48, 95% CI 1.68-40.13), treatment with Efavirenz/Tenofovir/Emtricitabine (OR 9.28, 95% CI 2.55-33.74) and treatment time antiretroviral older than 12 months (OR 2.53, 95% CI .912-7.041).</p><p><strong>Conclusion</strong>: The prevalence of prediabetes in people living with HIV is 46%. The main associated factor was the consumption of Atripla. This study has clinical relevance since it will allow the implementation of prevention, diagnosis and treatment strategies for prediabetes in order to reduce associated morbidity and mortality.</p><p><strong>Introducci贸n:</strong> la enfermedad por VIH ha pasado de ser un padecimiento mortal a uno con complicaciones metab贸licas. En la Ciudad de M茅xico se desconocen los factores asociados para prediabetes en esta poblaci贸n, investigarlo es relevante para mejorar su calidad de vida.</p><p><strong>Objetivo</strong>: determinar los factores con asociaci贸n de riesgo para prediabetes en personas que viven con VIH.</p><p><strong>Material y m茅todos</strong>: estudio transversal-anal铆tico, retrospectivo. Se revisaron expedientes de pacientes que viven con VIH, registr谩ndose los factores de exposici贸n y la concentraci贸n de glucosa en ayuno. Se incluyeron pacientes de 18 a 65 a帽os, en tratamiento antirretroviral coformulado, sin ajuste de tratamiento antirretroviral en los 煤ltimos dos a帽os, con IMC de 18.5-40 kg/m2.</p><p><strong>Resultados: </strong>se incluyeron 148 pacientes, 68 presentaron prediabetes. Los factores con asociaci贸n de riesgo que se identificaron son: edad mayor de 60 a帽os (OR: 9.48, IC95%: 1.68-40.13), tratamiento con Efavirenz/Tenofovir/Emtricitabina (OR: 9.28, IC95%: 2.55-33.74) y tiempo de tratamiento antirretroviral mayor de 12 meses (OR: 2.53, IC95%: 0.912-7.041).</p><p><strong>Conclusi贸n:</strong></p><p> la prevalencia de prediabetes en personas que viven con VIH es del 46%. El principal factor asociado fue el consumo de Atripla. Este estudio tiene relevancia cl铆nica ya que permitir谩 implementar estrategias de prevenci贸n, diagn贸stico y tratamiento de prediabetes con la finalidad de reducir la morbimortalidad asociada.</p>
